News tagged with genentech
FDA approves genetic test for lung cancer drug
The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.
Medications
May 14, 2013 |
not rated yet |
0
Engineered antibody demonstrated safety, efficacy in wide range of advanced tumors
(Medical Xpress)—The engineered antibody MPDL3280A, which targets a protein called programmed death-ligand 1 (PD-L1), was safe and effective for several cancers, according to phase I study results presented at the AACR ...
Cancer
Apr 10, 2013 |
4 / 5 (1) |
0
Novel chemotherapies more often used on- than off-label
(HealthDay)—In contemporary practice, medical oncologists use novel anticancer agents on-label more often than off-label, according to a study published online Feb. 19 in the Journal of Clinical Oncology.
Cancer
Feb 26, 2013 |
5 / 5 (1) |
0
Ranibizumab no better than saline for vitreous hemorrhage
(HealthDay)—For patients with vitreous hemorrhage from proliferative diabetic retinopathy (PDR), the probability of vitrectomy within 16 weeks after intravitreal injections of ranibizumab or saline is lower ...
Ophthalmology
Feb 01, 2013 |
not rated yet |
0
Cancer drugs give Roche a 2012 profit boost
Growing demand for its cancer medicines and diagnostic tests used by clinical laboratories helped Swiss drug maker Roche Holding AG post a modest 2.4 percent increase in full-year profits.
Other
Jan 30, 2013 |
not rated yet |
0
Bevacizumab doesn't prolong survival in stage II-III colon CA
(HealthDay)—For patients with stage 2 to 3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) does not prolong disease-free or overall survival, according ...
Cancer
Dec 12, 2012 |
not rated yet |
0
Science of placebos seen from alternative point of view
(Medical Xpress)—With the perspective of a scientist trained in acupuncture, Alison Adams is well positioned to explain why placebos may be misunderstood—and why they should be understood in the first ...
Medications
Nov 02, 2012 |
not rated yet |
0
Chemo combo promising for pancreatic neuroendocrine tumors
(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of ...
Cancer
Jul 13, 2012 |
not rated yet |
0
'Natural' protection against Alzheimer’s disease
deCODE Genetics, together with their colleagues from the pharmaceutical company Genentech, reported today in the journal Nature the discovery of a variant of the amyloid precursor protein (APP) gene that confers protection agains ...
Alzheimer's disease & dementia
Jul 11, 2012 |
not rated yet |
0
|
Perjeta approved for advanced breast cancer
(HealthDay) -- Perjeta (pertuzumab) has been approved by the U.S. Food and Drug Administration to treat people with HER2-positive late-stage breast cancer, the agency said in a news release.
Cancer
Jun 11, 2012 |
not rated yet |
0
ASCO: Continuing avastin with 2nd-line chemo ups survival
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal ...
Cancer
Jun 05, 2012 |
not rated yet |
0
Obesity, overweight at diagnosis ups B-cell lymphoma prognosis
(HealthDay) -- For U.S. veterans with diffuse large B-cell lymphoma (DLBCL), being overweight or obese at time of diagnosis correlates with improved survival, according to a study published online May 29 in ...
Cancer
May 30, 2012 |
not rated yet |
0
Trial set to see if drug can prevent Alzheimer's
(HealthDay) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.
Alzheimer's disease & dementia
May 16, 2012 |
5 / 5 (1) |
0
|
Avastin no benefit to older lung cancer patients: study
(HealthDay) -- Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer ...
Cancer
Apr 17, 2012 |
not rated yet |
0
|
Early response is an indicator for rectal cancer survival
(HealthDay) -- In patients with locally advanced rectal cancer undergoing radical resection, response to neoadjuvant chemoradiotherapy is an early marker that correlates with rates of recurrence-free survival, ...
Cancer
Apr 10, 2012 |
5 / 5 (1) |
0
Genentech
Genentech Inc., or Genetic Engineering Technology, Inc., is a biotechnology corporation, founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer. Trailing the founding of Cetus by five years, it was an important step in the evolution of the biotechnology industry. One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.
As of February 2011, Genentech employed more than 11,000 people. The Swiss pharmaceutical conglomerate Hoffmann-La Roche now completely owns Genentech after completing its purchase on March 26, 2009 for approximately $46.8 billion.
For more information about Genentech, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.